During the 24‑week period, participants are randomly assigned to one of the two groups and neither the participants nor the study staff know which treatment is given (double‑blind). Regular visits include blood tests that measure NT-proBNP, a protein that rises when the heart is under stress, and imaging tests such as an ultrasound of the heart (echocardiogram) that assess measurements like left ventricular end-diastolic volume index, left ventricular end-systolic volume index, E/e′ ratio, global longitudinal strain and left atrial volume index. Participants also complete the Kansas City cardiomyopathy questionnaire to report symptoms and quality of life, and a routine 12‑lead Electrocardiogram is performed to check the heart’s electrical activity. Throughout the study, safety is monitored by recording any side effects and checking routine laboratory values.

Participants will take the assigned medication for about three months. Their heart rhythm will be recorded using a portable device called a Holter-ECG, which continuously monitors the heart’s electrical activity for a week at the start of the study and again after three months. In addition, participants will answer simple questionnaires that measure overall well‑being, including the EQ-5D visual scale and the SF-12 health survey, to see how the treatment impacts daily life.

Throughout the study, any side effects such as fatigue, dizziness, low blood pressure, or more serious heart problems will be recorded. The need for additional procedures, such as a catheter-based technique to destroy the source of the extra beats, will also be noted. The overall goal is to find the safer and more effective option for managing these premature heartbeats.